Alvotech develops and produces biosimilar medications across multiple therapeutic categories including autoimmune disorders, ophthalmology, oncology, and bone health. The company's portfolio includes biosimilars designed to replicate treatments for conditions such as rheumatoid arthritis, psoriasis, Crohn's disease, age-related macular degeneration, cancer-related bone complications, and asthma, among others. Founded in 2013 and headquartered in Luxembourg, the firm operates through subsidiaries serving patients globally.

entry readiness 65 · MODERATE · exit proximity 0

Value area 3.01–5.24 · 46% of 120d volume overhead · moderate overhead